



DUALITY OF INTEREST DISCLOSURE FORM

Preamble

TrialNet is a clinical research program sponsored by the NIDDK, the NICHD, and the NIAID involving basic and clinical scientists worldwide. All TrialNet supported investigators, members, associates, support staff and any key personnel on any studies, are required to abide by the TrialNet Duality of Interest Policies and Procedures and complete appropriate TrialNet Duality of Interest Disclosure forms. TrialNet's policy establishes a process through which dualities will be reduced, eliminated or managed as necessary for all participants in TrialNet. We urge you to read the policy and form carefully so that you understand your duties that arise out of your participation in TrialNet.

In addition to submitting the TrialNet Duality of Interest Disclosure Form, you will be expected to comply with all local and institutional requirements regarding duality of interest (or designated as "conflict of interest" by home institution) and disclosure. You must submit documentation to the Executive Committee of any institutional review and/or notification of a duality(ies) pertinent to TrialNet studies that are planned or in progress.

Note: you must <u>sign and date each page</u> of the disclosure form before returning it to the TrialNet Coordinating Center.

DUALITY OF INTEREST DISCLOSURE FORM

Page 2/9

Disclaimer Agreement:

Your signature on this form indicates that you have read and agree to comply with TrialNet's Duality of Interest Policy. Furthermore, in filing the TrialNet Duality of Interest Disclosure Form, you

- Certify that the information you have submitted on the TrialNet Duality of Interest Disclosure Form is complete and accurate to the best of your knowledge.
- Understand that if you have any doubt as to whether or not you fall into a particular category for disclosure, you will supply TrialNet with the necessary background information so it can assist you in resolving the ambiguity.
- Accept that you will be required to update the TrialNet Duality of Interest Disclosure Form at all attended Steering Committee Meetings. In addition, you will be required to complete forms when a study(ies)/protocol(s) is submitted for review.
- Understand that you must continue to update the TrialNet Duality of Interest Disclosure Form for the tenure of your involvement with TrialNet.
- Agree that in the event that the TrialNet evaluation of your disclosure statement requires additional information, you will comply with the review committee's request and supply them with more detailed information.
- Understand that failure to complete the TrialNet Duality of Interest Disclosure Form accurately as requested may result in disqualification from TrialNet activity.

TrialNet will use the information contained in this disclosure form solely for TrialNet related purposes. All disclosures are confidential and will be kept in restricted access for review. Personal identifiers will be removed wherever possible and legally permissible. TrialNet maintains records of all financial disclosures and all actions taken by TrialNet with respect to each documented duality of interest. These records must be kept for the duration of the contract and then will be transferred to NIDDK for further storage.

1. DEFINITIONS	
Research	A systematic investigation designed to develop or contribute to generalizable knowledge.
TrialNet Investigator	An investigator at a TrialNet site, TrialNet Coordinating Center, the Chairman's Office, the NIH, Clinical Centers, Central Laboratories and/or other Central Facilities.
TrialNet Member	An individual associated with TrialNet Affiliates or Satellites.
TrialNet Associate	An individual not affiliated with a TrialNet Central Facility, Center, Affiliate, or Satellite who serves on TrialNet committees or as a collaborator or as a consultant.
TrialNet Supporting Staff	Individuals engaged in research other than TrialNet investigators at a TrialNet site, TrialNet Coordinating Center, the Chairman's Office, the NIH, Clinical Centers, Central Laboratories and/or other Central Facilities.
TrialNet Research Personnel Subject to Dualities of Interest	Principal investigators, investigators, and any other persons (including supporting staff) whose objectivity could reasonably influence the design, conduct, review and/or reporting of TrialNet research activity.

Sign and date this page in the	space below:		7/3/2003
Please Print Name	Signature	Date	

Employment	Full or part time work.					
Commercial Entity	Includes but is not limited to any company, business, firm, partnership or limited partnership. This also includes any TrialNet participants who have individual financial interests that are not covered by any of the above.					
Personal Duality of Includes but not limited to personal associations or professional collaborations that could affect scientific objectivity or commitment to a research endeavor.						
Affiliated Entity	One that owns, or is owned, or is subject to common ownership by any entity that is a participant in or is otherwise covered by TrialNet. For these purposes, ownership includes both direct and indirect ownership (ownership through intermediate entities).					
Intellectual Property	Includes but not limited to copyrights, patents, trademarks, trade names, and trade secrets.					
You	Refers to yourself, your spouse or dependents.					
2. PERSONAL INFOR	RMATION:					
Name:	WIATION.					
Institution:						
Address:						
Address.						
C il Addresse						
E-mail Address:						
Title/Role in TrialNet						
TrialNet Role: Investi	gator 🗖 Member 🗇 Associate 🗖 Support Staff 🗇 Other 🗖					
If Other, please indic	cate role or relationship:					
3. EMPLOYMENT						
in any medications, (intellectual property)	nployed by a commercial entity (or its affiliated entities) having an interest devices or intellectual property (or any competing medications, devices or that are utilized in a current TrialNet study(ies) or protocol(s) or may be sed for future use in a TrialNet study(ies) or protocol(s)? Yes No					
If yes, please provide disclosures.	the information requested below. See separate page attached for additional					
Commercial Entity	Medication/Device/Property Position Protocol/Study					
1						
2						
3						
Sign and data this new	o in the space helow:					
Sign and date this page	e in the space below: 7/3/2003					
 Please Print Name	Signature Date					
TIGOSE FILL INGILIE	oignature Date					

TrialNet Duality of Interest Di	isclosure		DU1
			Page
naving an interest in ar medications, devices o	red in the past two years by any medications, devices or in rintellectual property) that a considered or proposed for fu	tellectual proper re utilized in a cu	rty (or any competing urrent TrialNet study(ies) or
f yes, please provide the lisclosures.	information requested below.	See separate pag	ge attached for additional
Commercial Entity	Medication/Device/Property	<u>Position</u>	Protocol/Study
·			
·			
·			
Vithin the last two year	HONORARIA rs, have you served as a cor	nsultant and/or s	nonsored speaker and
eceived greater than \$	\$10,000 per year from any si	ngle commercial	entity (or its affiliated
,	rest in any medications, devi , devices or intellectual prop		
tudy(ies) or protocol(s) or may be considered or pr		
tudy(ies) or protocol(s	<i>,</i> — —		
yes, please provide the isclosures.	information requested below.	See separate pag	ge attached for additional
Commercial Entity	Medication/Device/Property	<u>Activity</u>	Protocol/Study
·			
·			
·			
ign and date this page in	the space below:		7/3/2003
			<u> </u>

5. STOCK OWNERSH	IP (Not publicly traded en	tity)	
Do you have ownership commercial entity (or its has an interest in any nedications, devices or	o interests (including stock of s affiliated entities), the stoce nedications, devices or intel r intellectual property) that a onsidered or proposed for for	ptions), valued at gr k of which is not pub lectual property (or a are utilized in a curre	olicly traded and which any competing nt TrialNet study(ies) or
If yes, please provide the disclosures.	information requested below.	See separate page a	ttached for additional
Commercial Entity	Medication/Device/Property	Type of Ownership	Protocol/Study
1			
2			
3			
6. STOCK OWNERSH	IP (Publicly traded entity)		
intellectual property (or utilized in a current Tria future use in a TrialNet If yes, please provide the disclosures.	s affiliated entities) having a any competing medications alNet study(ies) or protocol(s study(ies) or protocol(s)? information requested below.	s, devices or intellect s) or may be conside Yes No See separate page a	tual property) that are ered or proposed for ttached for additional
Commercial Entity	Medication/Device/Property	Type of Ownership	Protocol/Study
1			
2			
3			
Sign and date this page in	the space below:		7/3/2003

7. INTELLECTUAL PR	ROPERTY		
Do you have any pater competing intellectual	nts, patents pending, or othe property) that are utilized in a per proposed for future use in	a current TrialNet	t study(ies) or protocol(s)
If yes, please provide the disclosures.	e information requested below.	See separate pag	ne attached for additional
Intellectual Property	Protocol/Study		
3			
	ESEARCH AND CLINICAL sic or clinical research fundin		
intellectual property) th considered or proposed	r intellectual property (or any at are utilized in a current Trud for future use in a TrialNet information requested below.	ialNet study(ies) study(ies) or pro	or protocol(s) or may be tocol(s)?
Commercial Entity	Medication/Device/Property	<u>Position</u>	Protocol/Study
1			
2			
3			
Sign and date this page in	the space below:		7/3/2003
Please Print Name	Signature		

Sign and date this page in	n the space below:		7/3/2003
activities.		-	
commercial research o	organization and/or interests co	ompeting with TrialNet not indicate t with regard to any of your TrialNe	
Please indicate in the s	•	rests, involvement with a non-	
3			
2			
Commercial Entity 1	MedicationDevice/Property	Protocol/Study	
disclosures.	e iniormation requested below. S	See separate page attached for additi	onai
	protocol(s)?	See concrete name attached for additi	ional
	rotocol(s) or may be consider	ed or proposed for future use in a	
any competing medica	tions, devices or intellectual p	roperty) that are utilized in a curre	y (O:
affiliated entities) having any competing medicar	ng an interest in any medication tions, devices or intellectual p		

ADDITIONAL DUALITIES

Commercial Entity Medication/Device/Property Position Protocol/Study 1
2.
2.
3
A. CONSULTANCIES/ HONORARIA Commercial Entity Medication/Device/Property Activity Protocol/Study 1
Commercial Entity Medication/Device/Property Activity Protocol/Study 1
1
2
3
5. STOCK OWNERSHIP (Not publicly traded entity) Commercial Entity Medication/Device/Property Type of Ownership Protocol/Study 2
Commercial Entity Medication/Device/Property Type of Ownership Protocol/Study 2
1.
1.
2.
3
(and of the state
Commercial Entity Medication/Device/Property Type of Ownership Protocol/Study
2
7. INTELLECTUAL PROPERTY
Intellectual Property Protocol/Study
1
2
3
Sign and date this page in the space below: 7/3/2003
1/3/2003
Please Print Name Signature Date

. BASIC SCIENCE RI	ESEARCH AND CLINICAL TRIA	AL RESEARCH FUN	DING
Commercial Entity	Medication/Device/Property	<u>Position</u>	Protocol/Study
			_
			_
			
MEMBERSHIP ON I	BOARD OF DIRECTORS OR A	DVISORY COMMIT	TEE
Commercial Entity	MedicationDevice/Property	Protocol/Study	
			_
			_
			_
. OTHER DUALITIE	S OF INTEREST		
Sign and date this page i	in the space below:		7/3/2003

TRIALNET: DUALITY OF INTEREST DISCLOSURE UPDATE FORM For Change In Duality Status

DU2 Page 1/8

This form should be used to indicate any new duality(ies) of interest since your last report. Also, if a duality(ies) previously reported no longer exists, please indicate.

1. DEFINITIONS	
Research	A systematic investigation designed to develop or contribute to generalizable knowledge.
TrialNet Investigator	An investigator at a TrialNet site, TrialNet Coordinating Center, the Chairman's Office, the NIH, Clinical Centers, Central Laboratories and/or other Central Facilities.
TrialNet Member	An individual associated with TrialNet Affiliates or Satellites.
TrialNet Associate	An individual not affiliated with a TrialNet Central Facility, Center, Affiliate, or Satellite who serves on TrialNet committees or is a collaborator or as a consultant.
TrialNet Supporting Staff	Individuals engaged in research other than TrialNet investigators at a TrialNet site, TrialNet Coordinating Center, the Chairman's Office, the NIH, Clinical Centers, Central Laboratories and/or other Central Facilities.
TrialNet Research Personnel Subject to Dualities of Interest	Principal investigators, investigators, and any other persons (including supporting staff) whose lack of objectivity could reasonably influence the design, conduct, review and/or reporting of TrialNet research activity.
Employment	Full or part time work.
Commercial Entity	Includes but is not limited to any company, business, firm, partnership or limited partnership. This also includes any TrialNet participants who have individual financial interest that are not covered by any of the above.
Personal Duality of Interest	Includes but not limited to personal associations or professional collaborations that could affect scientific objectivity or commitment to a research endeavor.
Affiliated Entity	One that owns, or is owned, or is subject to common ownership by any entity that is a participant in or is otherwise covered by TrialNet. For these purposes, ownership includes both direct and indirect ownership (ownership through intermediate entities).
Intellectual Property	Includes but not limited to copyrights, patents, trademarks, trade names, and trade secrets.
You	Refers to yourself, your spouse or dependents.

Sign and date this page in the space below:			
Please Print Name	Signature	Date	11/20/02

TRIALNET: DUALITY OF INTEREST DISCLOSURE UPDATE FORM For Change In Duality Status

	2. PERSONAL INFOR	RMATION:			
	Name:				
	Institution:				
	Address:				
	E-mail Address:				
	Title/Role in TrialNet				
Tri	alNet Role: Investig	gator 🗖 Member 🗖 A	ssociate 🗖 S	upport Staff 🗖	Other \square
	Other, please indicate ro				
3.	EMPLOYMENT				
If ye	ality(ies) please check A) or protocol(s)? information requested below A. If this is a duality that is i ed for additional disclosures	no longer applica		
	Commercial Entity	Medication/Device/Property	<u>Position</u>	Protocol/Study	
1.					
2			_		$\overset{A}{\square} \overset{B}{\square}$
- .	 -			- 	A B
3.					
Sigr	n and date this page in the s	space below:			
Ple	ease Print Name	Signature		Date	 11/20/02

4. CONSULTANCIES/HONORARIA

speaker and received greaffiliated entities) having a competing medications, d study(ies) or protocol(s) or protocol(s)? YES	ge in your duality of interest atter than \$10,000 per year from interest in any medication levices or intellectual propertor may be considered or propertor NO	rom any single o s, devices or int y) that are utiliz osed for future	commercial entity (cellectual property (ed in a current Triause in a TrialNet st	or its or any INet udy(ies	s) or
duality(ies) please check	A. If this is a duality that is need for additional disclosures	o longer applica	•		
Commercial Entity	Medication/Device/Property	<u>Activity</u>	Protocol/Study		
1					
2				A	
				A	В
o				A	В
5. STOCK OWNERSHIP	(Not publicly traded entity	<i>(</i>)			
entities), the stock of which devices, or intellectual pro- that are utilized in a curre- future use in a TrialNet sto- lf yes, please provide the duality(ies) please check	valued at greater than \$10,0 ch is not publicly traded and operty (or any competing ment TrialNet study(ies) or protoudy(ies) or protocol(s)? Information requested below A. If this is a duality that is not pred for additional disclosures	which has an indications, device ocol(s) or may be seen to the seen the see	terest in any medic es or intellectual prope considered or pro NO ddition to your list o	ations, operty) oposed)
Commercial Entity	Medication/Device/Property		Protocol/Study		
1					
2				Å	В
				Ā	ВВВ
Sign and date this page in the	space below:				
Please Print Name	Signature		Date	11	/20/02

6. STOCK OWNERSHIP (Publicly traded entity)

(including stock options, b greater than \$10,000 in a p interest in any medications devices or intellectual prop may be considered or prop TYES NO If yes, please provide the in	ge in your duality of interest ut excluding indirect investre publicly traded commercial is, devices, or intellectual property) that are utilized in a coosed for future use in a Trick information requested below A. If this is a duality that is in	nents through mentity (or its affile operty (or any concurrent TrialNet salNet study(ies) w. If this is an accurrent and accurrent this is an accurrent the study (ies)	nutual funds), valued iated entities) havin ompeting medication tudy(ies) or protocol or protocol(s)?	d at g an ns, ol(s) or	
•	ed for additional disclosures	•	, ,		
Commercial Entity	Medication/Device/Property	Type of <u>Ownership</u>	Protocol/Study		
1.					
				A	В
				A	В
3				A	В
7. INTELLECTUAL PROF					_
forms of intellectual proper TrialNet study(ies) or proto study(ies) or protocol(s)? [If yes, please provide the induality(ies) please check is See separate page attache	information requested below A. If this is a duality that is red ed for additional disclosures	ectual property) to dor proposed for proposed for the second seco	that are utilized in a per future use in a Tri	curren ialNet f	nt
Intellectual Property	Protocol/Study				
1					
2.			В		
		A	В		
J		A	В		
Sign and date this page in the s	space below:				
Please Print Name	Signature		Date	11,	/20/02

8. BASIC SCIENCE RESEARCH AND CLINICAL TRIAL RESEARCH FUNDING

funding you have received commercial entity (or its a intellectual property (or ar utilized in a current TrialN use in a TrialNet study(ies	ge in your duality of interest d totaling greater than \$30,0 affiliated entities) having an interest distributed entities and the competing medications, due to study(ies) or protocol(s)? Tes	00 over the last interest in any meterices or intelled or may be considered NO	three years from a edications, devices ctual property) that lered or proposed f	or are for future	е
duality(ies) please check	information requested below A. If this is a duality that is need for additional disclosures	no longer applica			
Commercial Entity	Medication/Device/Property	<u>Position</u>	Protocol/Study		
1 2				A A	В
				A	B B
9. MEMBERSHIP ON BO	DARD OF DIRECTORS OR	ADVISORY CO	MMITTEE		
Committees on which you in any- medications, device intellectual property) that a considered or proposed for lf yes, please provide the duality(ies) please check in the committee of the duality (ies) please check in the committee of the committ	in your duality of interest states a serve for a commercial entioner, or intellectual property (are utilized in current TrialNet or future use in a TrialNet state information requested below A. If this is a duality that is need for additional disclosures	ity (or its affiliate or any competing et study(ies) or protocute. If this is an action longer application.	d entities) having a g medications, devorotocol(s) or may be col(s)? TYES	in intere rices or be NO	est
Commercial Entity	Medication/Device/Property	Protocol/Study			
_			A B		
2			A B		
Sign and date this page in the	space below:				
Please Print Name	Signature		Date	11/2	20/02

10. OTHER DUALITY(IES) OF INTEREST

10. OTHER DUALITY (IES) OF INTER	LSI		
Please indicate in the space below any research organization and/or interests of perceived as a duality of interest with re-	competing with TrialNe	t not indicated above that	nercial could be
			<u>.</u>
			
Sign and date this page in the space below:			
Please Print Name	Signature	Date	11/20/02

TRIALNET: DUALITY OF INTEREST DISCLOSURE UPDATE FORM For Change In Duality Status ADDITIONAL DUALITIES

DU2 Page 7/8

	7 (3 3 1 1 1 3 1 1 1 2 3 2 1	<u> </u>	
3. EMPLOYMENT			
Commercial Entity	Medication/Device/Property Po	<u>osition</u>	Protocol/Study
1			<u> </u>
2			
3			
4. CONSULTANCIES/	HONORARIA		
Commercial Entity	Medication/Device/Property	<u>Activity</u>	Protocol/Study
1			
2			
3			
5. STOCK OWNERSH	IP (Not publicly traded entity)		
Commercial Entity	Medication/Device/Property	Type of Ownership	Protocol/Study
1		_	<u> </u>
2			
3			
6. STOCK OWNERSH	IP (Publicly traded entity)		
Commercial Entity	Medication/Device/Property	Type of Ownership	<u>Protocol/Study</u>
1			
2			
3			

Sign and date this page in the space below:			
Please Print Name	Signature	Date	11/20/02

TRIALNET: DUALITY OF INTEREST DISCLOSURE UPDATE FORM For Change In Duality Status

DU2 Page 8/8

	- continued in a continued in the contin		
7. INTELLECTUAL PRO	PERTY		
Intellectual Property	Protocol/Study		
3		<u></u>	
8. BASIC SCIENCE RES	SEARCH AND CLINICAL TRIA	AL RESEARCH FUNI	DING
Commercial Entity	Medication/Device/Property	<u>Position</u>	Protocol/Study
1		-	-
2			
3			
9. MEMBERSHIP ON BO	DARD OF DIRECTORS OR A	DVISORY COMMITT	EE
Commercial Entity	MedicationDevice/Property	Protocol/Study	
1			_
2			-
3			-
10. OTHER DUALITIES	OF INTEREST		
TO. OTHER DOALITIES	OF INTEREST		
	ace below any personal interes		
	d/or interests competing with T interest with regard to any of y		
porconvou do a adamy or	intoroot with rogard to drift or y	our man vot douvidoo.	•
Sign and date this page in the	space below:		
- , ,			

Signature

Date

11/20/02

Please Print Name

TRIALNET

DU3 Page 1/1

DUALITY OF INTEREST FORM For Assertion of No Change In Duality Status

I assert that there has been no change in my duality of interest status since my last statement.

Name:			
Institution:			
Address:			
E-mail Address:			
<u>rialNet Role</u> : Investigator	□ Member □ Associate □	Support Staff	Other \square
Other, please indicate role of	r relationship:		
Please sign and date this pa	ge in the space below:		
Please sign and date this pa	ge in the space below:		
Please sign and date this pa	age in the space below: Signature		Date



To: All October 2004 Steering Committee Meeting Attendees

From: TrialNet Coordinating Center

Subject: Company Listing for updating Duality of Interest Status

Date: 9/15/2004

As noted by Jay Skyler, TrialNet Type 1 Diabetes Study Chairman, the following companies have products under consideration for TrialNet studies:

Amylin Pharmaceuticals and Eli Lilly & Co – Exenatide
Autoimmune and Eli Lilly & Co – Oral insulin
Bristol-Myers-Squibb - CTLA4-Ig
Chiron – IL-2
Genentech & IDEC Pharmaceuticals – (Anti-CD20) - Rituximab
Martek (formerly Omega Tech) – Omega 3 Fatty Acids
Mead- Johnson Nutrionals – Enfamil and Lipil Infant Formulas
Neurocrine, Inc. - Insulin B9-23-APL
Peptor, Inc. and Aventis,Inc. - DiaPep277
Roche, Inc.- Mycophenolate mofetil (MMF)
Roche, Inc. and Protein Design Labs, Inc. (PDL) - Anti-CD25 (Daclizumab)
Wyeth – Rapamune (sirolimus)

This list is not to be construed as comprehensive, as other products may come up for review. Moreover, it is possible that a duality may arise by virtue of a relationship with a company that has a competitive product not currently under consideration for a TrialNet study.



Please Print Name

TRIALNET: CONFIDENTIALITY AGREEMENT Type 1 Diabetes TrialNet Study Group

This form must be signed by all TrialNet investigators, TrialNet Associates, TrialNet Members, and any others who would have access to any proprietary information related to any TrialNet study.

The undersigned is a participant in the Type 1 Diabetes TrialNet Study Group. The undersigned recognizes that in the course of evaluating potential interventions and conducting other TrialNet Study Group business, certain information of a confidential and/or proprietary nature will be provided, and that improper use of such information could damage an institution, a business, or another entity. The undersigned agrees not to disclose any such information to any third party or use it for any purpose except as indicated by the TrialNet Study Group. The undersigned agrees to take all precautions to avoid the unauthorized disclosure or use of such confidential information. The undersigned agrees that this applies to material provided in writing, orally, and to any notes taken. The undersigned will take all reasonable measures to protect the secrecy of the information and will notify the TrialNet Coordinating Center of any misuse or disclosure which comes to his/her attention.

The undersigned shall have no obligation of confidentiality or non-use with respect to any portion of information disclosed hereunder which (a) is or later becomes generally available to the public by use, publication or the like; (b) is obtained from a third party without restriction who had the legal right to disclose the same; (c) the undersigned already possesses, as evidenced by his/her written records, predating receipt thereof from TrialNet; or (d) is independently developed by the undersigned as conclusively evidenced by written records.

PERSONAL INFORMATION:	
Name:	
Institution:	
Address:	
E-mail Address:	
Title/Role in TrialNet	
TrialNet Role: Investigato	r □ Member □ Associate □ Support Staff □ Other □
If Other, please indicate role:	
	rm for completion by other TrialNet personnel at your site as needed, and atting Center, George Washington University, Biostatistics Center, 50, Rockville, MD 20852.
Please sign and date this page in t	he space below and return it to the TrialNet Coordinating Center.

Date

Signature